Droxidopa clinical trials
Also written Northera, L-DOPS and L-threo-DOPS.
How each study uses Droxidopa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Droxidopa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Feb 2014 · NORTHERA · NDA 203202 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 22
Chelsea Therapeutics (14) · Vanderbilt University Medical Center (2) · St. Joseph's Hospital and Medical Center, Phoenix (2) · Stephen G. Kaler, MD (1) · University Hospital, Toulouse (1) · James J. Peters Veterans Affairs Medical Center (1) · H. Lundbeck A/S (1) · Alberto Espay, MD, MSc (1)
Often tested with
Tested in the same studies.
Carbidopa (4) · Midodrine (1) · Atenolol (1) · Entacapone (1)
Related medicines
As reviewed, each with the page that says it.
- A prodrug of Norepinephrine source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Droxidopa.
- May 2027Droxidopa / Pyridostigmine in Orthostatic HypotensionPhase 2 · Mayo Clinic
Studies
Open first, then newest update. How each study uses Droxidopa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 38
- NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes DiseaseRecruitingPhase 1/2Stephen G. KalerNCT07398508Written as Droxidopa Oral Product
- Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney InjuryRecruitingPhase 2Giuseppe Cullaro, MDNCT06937307Written as Droxidopa capsules
- Droxidopa / Pyridostigmine in Orthostatic HypotensionEnrolling by invitationPhase 2Mayo ClinicNCT01370512Written as Droxidopa
- Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureTerminatedPhase 1Vanderbilt University Medical CenterNCT02897063Written as Droxidopa
- NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn SyndromeCompletedPhase 1/2Stephen G. Kaler, MDNCT04977388Written as Droxidopa
- Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSACompletedPhase 2/3University Hospital, ToulouseNCT02071459Written as L-Threo DOPS
- Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord InjuryCompletedPhase 4James J. Peters Veterans Affairs Medical CenterNCT03602014Written as Northera
- Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of CarbidopaCompletedPhase 2Chelsea TherapeuticsNCT00983814Written as Droxidopa+Carbidopa
- Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With FibromyalgiaCompletedPhase 2Chelsea TherapeuticsNCT01323374Written as Droxidopa
- Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)CompletedPhase 3Chelsea TherapeuticsNCT01132326Written as Droxidopa
- Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic HypotensionCompletedPhase 4H. Lundbeck A/SNCT02586623Written as Droxidopa capsules
- Lundbeck TOMs Orthostatic HypotensionCompletedPhase 4Alberto Espay, MD, MScNCT04510922Written as Droxidopa 100 MG [Northera]
- Brain Perfusion & Oxygenation in Parkinson's Disease With NOHCompletedPhase 4William Ondo, MDNCT03229174Written as Droxidopa
- Treatment of Orthostatic HypotensionTerminatedPhase 2/3Vanderbilt UniversityNCT00581477Written as Droxidopa Oral Product
- Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismWithdrawnPhase 2Loma Linda UniversityNCT03446807Written as Droxidopa
- A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's DiseaseTerminatedPhase 4The Cooper Health SystemNCT03034564Written as Northera
- Norepinephrine-targeted Therapy for Action Control in Parkinson DiseaseCompletedPhase 4Vanderbilt University Medical CenterNCT03115827Written as Droxidopa
- Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)Status unknownPhase 2St. Joseph's Hospital and Medical Center, PhoenixNCT03567447Written as Droxidopa
- Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson DiseaseStatus unknownPhase 2St. Joseph's Hospital and Medical Center, PhoenixNCT02812147Written as L-DOPS
- Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's DiseaseCompletedNot applicableColorado Springs Neurological AssociatesNCT03173781Written as droxidopa
What changed recently
From the registry's own updates since Oct 19, 2026.
Stopped1
- Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureTerminatedOct 23, 2026NCT02897063
Codes
What other systems call Droxidopa · ClinicalTrials.gg INT008438
- MeSH (NLM) D015103DroxidopaConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) J7A92W69L7DROXIDOPAConfirmed FDA, NLM, Wikidata
- RxNorm 1489913Confirmed FDA, Wikidata
- Wikidata Q907853droxidopaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73266DroxidopaConfirmed FDA, Wikidata
- DrugBank DB06262One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015103 | Droxidopa | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | J7A92W69L7 | DROXIDOPA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1489913 | — | Confirmed FDA, Wikidata |
| Wikidata | Q907853 | droxidopa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73266 | Droxidopa | Confirmed FDA, Wikidata |
| DrugBank | DB06262 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.